Capital Analysts LLC Purchases New Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Capital Analysts LLC purchased a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,616 shares of the company’s stock, valued at approximately $102,000.

Other institutional investors have also bought and sold shares of the company. Robeco Institutional Asset Management B.V. boosted its stake in Teva Pharmaceutical Industries by 7.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after buying an additional 33,277 shares in the last quarter. Pinnbrook Capital Management LP bought a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $4,966,000. Asset Management One Co. Ltd. raised its position in Teva Pharmaceutical Industries by 14.6% in the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock valued at $10,414,000 after purchasing an additional 58,413 shares during the last quarter. CWA Asset Management Group LLC bought a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $3,340,000. Finally, Allspring Global Investments Holdings LLC raised its position in Teva Pharmaceutical Industries by 2,018.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company’s stock valued at $23,368,000 after purchasing an additional 1,045,305 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 1.1 %

NYSE TEVA opened at $15.03 on Tuesday. The stock has a 50-day simple moving average of $15.19 and a 200 day simple moving average of $17.55. The company has a market capitalization of $17.04 billion, a PE ratio of -10.37, a P/E/G ratio of 1.44 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12 month low of $12.47 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on TEVA shares. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. Bank of America cut their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Barclays dropped their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. UBS Group dropped their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Finally, Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.